Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
NCT ID: NCT00135382
Last Updated: 2010-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
254 participants
INTERVENTIONAL
2002-06-30
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen
NCT00135369
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
NCT00158821
Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125
NCT00792324
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01495702
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
NCT00013520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Videx EC
Epivir
Sustiva
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age and weight at least 40kg
* Two plasma HIV RNA levels \< 50 copies/mL during the qualification and screening period
* Patients receiving a PI and ≥ 2 NRTIs
Exclusion Criteria
* Documented virologic failure while on their first PI-based antiretroviral (ARV) regimen
* Active AIDS-defining opportunistic infection or disease
* Proven or suspected acute hepatitis within 30 days prior to study entry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Little Rock, Arkansas, United States
Local Institution
Beverly Hills, California, United States
Local Institution
Fountain Valley, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
San Diego, California, United States
Local Institution
San Francisco, California, United States
Local Institution
Tarzana, California, United States
Local Institution
West Hollywood, California, United States
Local Institution
Denver, Colorado, United States
Local Institution
Norwalk, Connecticut, United States
Local Institution
Washington D.C., District of Columbia, United States
Local Institution
Atlantis, Florida, United States
Local Institution
Daytona Beach, Florida, United States
Local Institution
Fort Lauderdale, Florida, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Miami, Florida, United States
Local Institution
Miami Beach, Florida, United States
Local Institution
North Miami, Florida, United States
Local Institution
Orlando, Florida, United States
Local Institution
Plantation, Florida, United States
Local Institution
Safety Harbor, Florida, United States
Local Institution
South Miami, Florida, United States
Local Institution
Tampa, Florida, United States
Local Institution
Atlanta, Georgia, United States
Local Institution
Decatur, Georgia, United States
Local Institution
Chicago, Illinois, United States
Local Institution
Boston, Massachusetts, United States
Local Institution
Springfield, Massachusetts, United States
Local Institution
Kansas City, Missouri, United States
Local Institution
St Louis, Missouri, United States
Local Institution
East Orange, New Jersey, United States
Local Institution
Newark, New Jersey, United States
Local Institution
Union, New Jersey, United States
Local Institution
Brooklyn, New York, United States
Local Institution
Manhasset, New York, United States
Local Institution
Mount Vernon, New York, United States
Local Institution
New York, New York, United States
Local Institution
Stony Brook, New York, United States
Local Institution
Valhalla, New York, United States
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Columbia, South Carolina, United States
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
Hampton, Virginia, United States
Local Institution
Milwaukee, Wisconsin, United States
Local Institution
Ponce, , Puerto Rico
Local Institution
Rio Piedras, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI266-406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.